Genetic blueprint guides new lymphoma cocktail
NCT ID NCT07706959
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests whether adding targeted drugs (azacitidine or decitabine plus selinexor) to standard chemotherapy improves outcomes for people newly diagnosed with peripheral T-cell lymphoma. Participants are assigned treatment based on their tumor's genetic profile. The study first finds the safest dose, then compares the personalized combination against standard chemo alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azacitidine or decitabine plus selinexor combined with CHOP chemotherapy
- What this could lead to
- If successful, this approach could offer a more personalized, effective treatment for peripheral T-cell lymphoma by targeting specific genetic mutations.
- What could go wrong
- This is an early-phase trial, so the safety and effectiveness of the combination are not yet proven. The added drugs may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA (PTCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.